

Research Tips
University of Colorado Denver
Vice Chancellor for Research:RJ Traystman

10/01/2009 | Volume 1 Issue 3

Stimulus Funding Update (ARRA)

As of September 28, 2009, UCDenver submitted 574 ARRA and 24 non-ARRA grant proposals to NIH. Thus far 93 have been funded for a total of $37,915,575.

COMIRB InfoEd Training

COMIRB will begin training sessions on our new electronic system. The new system will enable you to access information on the status of your protocols in a manner similar to the old protocol manager. Training will also provide information on electronic submission of protocols. COMIRB hopes to begin the process of accepting documents electronically in November and will start with the Request for Exemption form. Training sessions will begin October 6 and will be held twice a week until the end of the year in Ed2 North (AMC) room 2201AB. This room holds 30 on a first come first served basis.

Nov. 3	1pm - 3pm	Nov. 12	10am - 12pm
Nov. 5	9am - 11am	Nov. 17	1pm - 3pm
Nov, 10	2pm - 4pm	Nov. 19	9am - 11am

Biosafety

The NIH Office of Biotechnology Activities (OBA; http://oba.od.nih.gov/oba/index.html), in their role administering NIH Guidelines for Research Involving Recombinant DNA Molecules (http:// oba.od. nih.gov/oba/rac/ uidelines_02/NIH_Guidelines_Apr_ 02.htm), has recently published a brochure on Investigator Responsibilities for Research Involving Recombinant DNA Molecules (http:// oba.od.nih.gov/oba /ibc/InvestigatorEducationalBrochureRecombinant %20D NA.pdf). A limited number of hard-copy versions have been provided by NIH OBA. We encourage you to review this information at NIH OBA website (http://oba. od.nih.gov/oba/index.html or contact our office for a copy (303-724-0235; biosafety.program@ucdenver. edu). Please contact UCDenver Institutional Biosafety Committee (http://www.uchsc.edu/safety/BioSafety /InstBioSafCommittee.htm) or the Biosafety Office for additional information.

Dr. T's Corner

New NIH Director - Francis S. Collins, MD, PhD, was sworn in as the 16th Director of the National Institutes of Health (NIH) on August 7, 2009. Dr. Collins was raised on a farm in the Shenandoah Valley in Virginia and was home schooled by his mother until the sixth grade. He received his BS in Chemistry in 1970 from University of Virginia and a PhD in Physical Chemistry from Yale in 1974. He received the MD in 1977 from University of North Carolina (UNC) at Chapel Hill. He did a residency in internal medicine at UNC and then a Fellowship in human genetics at Yale until 1984. He then joined the faculty at University of Michigan. Dr. Collins has led the Human Genome Project and directed the National Human Genome Research Institute (NHGRI) at NIH, and he established the BioLogos Foundation, which addresses the interface between science and faith. Dr. Collins is a physician-geneticist who has made seminal discoveries of disease genes. As Director of NIH, he has announced five priority areas: 1) applying new technologies to the understanding of basic biology and the causes of specific diseases; 2) translational research; 3) putting science to work for health care reform; 4) global health; and 5) achieving a stable and predictable funding trajectory for biomedical research. Dr. Collins' career has not been without controversy, particularly considering his outspoken views regarding religion and faith. His 2006 book "The Language of God: A Scientist Presents Evidence for Belief" is a most interesting read. In his private life, Dr. Collins is a rock guitarist and while at NHGRI formed a rock band (called the "Directors") with other NIH investigators. His is also very fond of motorcycles.

COMIRB

What training courses do I need? Where do I find them? UCDenver employees submitting to COMIRB, UCDenver employees submitting to HSRC, and Non-UCDenver affiliates: CITI Basic Course www.citiprogram.org). HIPPA Research Training Course - SkillPort on https://my.cu.edu.

COMIRB complete instructions: http://comirbweb.uchsc.edu under COMIRB Education.
HSRC complete instructions: http://comirbweb.uchsc.edu/hsrc

Note: If you need to take any of the above named training courses or request a POI number in order to submit a protocol to COMIRB, please register with COMIRB by calling the Help Desk at 303-724-1055 so that your human subject training can be tracked appropriately.

Safety Tip - Please Remove Your Gloves When They Are Not Immediately Needed

Please remember to remove your gloves when you are not directly handling animals, reagents, or drugs, especially when opening doors, walking down hallways, operating elevators, picking up phones, etc. Even though you know that your gloves are clean, those around you do not. This can be very disturbing to your co-workers. In addition, in the animal facility, it is extremely important because viruses, such as parvovirus, can live for a long time on inanimate objects. For example, if you touch a door handle with a gloved hand and then your mice, you may inadvertantly spread infections.

Research Corner

Congestive heart failure is an enormously prevalent disease in Western society. It is associated with substantial morbidity and mortality as well as with staggering health care costs. Contemporary pharmacotherapy is often quite effective in preventing and even reversing disease progression; however, it is difficult to predict which patients will and will not respond. This issue is particularly important because current treatment strategies include costly interventions, such as implantable cardiac defibrillators, artificial hearts, and cardiac transplantation. The subset of patients who don't respond to pharmacotherapy truly benefit from early advanced interventions before their disease has progressed or they have developed morbid complications. Dr. Brian Lowes, Prof. of Medicine, Cardiology Division, is leading a multi-disciplinary team of investigators addressing this issue. Their preliminary data suggests that molecular profiles obtained from endomyocardial biopsies can identify patients who are at high risk for disease progression, despite optimal medical treatment. Their algorithm is being developed from mRNA profiling, microRNA arrays, and quantitative proteomic assays on tissue obtained from the intact human heart. A predictive algorithm using these biomarkers represents the first multiplexed in vivo molecular diagnostic of the human heart. The goal of this research is to translate our molecular understanding of heart failure into clinical tools that can guide the diagnosis, classification, and management of these patients. The research is being conducted on both inpatient and outpatient units of the CCTSI. It involves our bioinformatics, proteomics, and gene expression core facilities. The investigators are hopefull that they will be able to continue their research through a Cardiac Translational Implementation Program (CTRIP) which currently is under review at NHLBI. The objective of CTRIP is to accelerate translation of promising new discoveries for treatment of heart failure into the planning and execution of clinical trials. The Colorado Prevention Center, a clinical trials organization affiliated with our University, is aiding in trial design and execution. Our Technology Transfer office has assisted in filing preliminary patents for these discoveries. The research has been supported by NIH, the University of Colorado Cardiovascular Institute, and the departments of Pharmacology and Cardiology. Dr. Lowes received his Internal Medicine and Cardiology training here at the University of Colorado and is a byproduct of our Clinical Sciences Training Program.

ORDE

The Office of Research Development and Education (ORDE) invites the (all UCDenver Faculty)University Research Community to an open forum discussion of "Collaboration in Research" to be held on Thursday, October 8th. This Faculty Discussion Panel will help participants define a true collaboration, learn the advantages associated with research collaborations and develop strategies for setting up and managing effective collaborations. This event is an excellent chance to listen to and share information among your colleagues in the University Research Community. The format involves a short introduction from Associate Vice Chancellor for Research, James H. Hageman who will also serve as panel moderator. This will be followed by commentary from our faculty panelists and then a question-and-answer discussion. Our Faculty Panelists are: George S. Eisenbarth, Executive Director of the Barbara Davis Center, Paula A. Espinoza, Assistant Professor of Ethnic Studies and PI in the Latino/a Research and Policy Center, Amy Brooks-Kayal, Chief and Ponzio Chair of Pediatric Neurology. Please join us from 10:30am - 12:30pm on October 8th in Education 2North, Lecture Hall P28-1303 at the Anschutz Medical Campus.

This fall we will continue the ORDE curriculum with our seminar, "Your Research: The Building Blocks of Proposals" in October and two presentations of our seminar, "Preparation for Proposal Writing: Strategic Elements of Success" in November. All three of these seminars are full but feel free to put your name on our waiting list. In the past when the waitlist reached a seminar size threshold, we have created an additional presentation. In the Spring our curriculum will include the seminars, "Funding Fundamentals", " Funding Plan: Creating Sustainability". We will have another open forum discussion in the Spring, "Peer Review".

Office of Grants and Contracts
Fall 2009 - Contracts and Policy

The National Institutes of Health published its final Guidelines on Human Stem Cell Research. The Guidelines, effective July 7, 2009, outline the conditions under which NIH will fund human embryonic stem cell (hESC) research. To review NIH's hESC Guidelines, go to the following link: http:// stemcells.nih.gov/policy/2009guidelines.htm. Frequently Asked Questions can be found at: http://stemcells.nih.gov/info/faqs.asp#funding.

Do you have questions about export control? Check out A Guide for Understanding Export Control Laws and Regulations on the OGC website: http://www.uchsc.edu/ogc/. The Guide provides a summary of the type of items which are subject to export control laws. The Guide also outlines the type of research activities which may involve export control, as well as the different areas in which export issues may arise. Further questions can be directed to the individuals listed in the Guide.